Slávka Lukacova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Slávka Lukacova has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Jesper Folsted Kallehauge
Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
4 shared publications - Aida Muhic
Department of Oncology, Copenhagen University Hospital, Rigshospitalet , Copenhagen
2 shared publications - Christian Rønn Hansen
Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
2 shared publications - Céline Aubin
Servier International , Suresnes
2 shared publications - Giuseppe Lombardi
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
2 shared publications - Jane Skjøth-Ramussen
Department of Neurosurgery, Neuroscience Center, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
2 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 180 (2)
Long-term socioeconomic, psychiatric, and societal burden in patients with grade 2 mIDH glioma and partner spillover burden, worsening with disease progression and RT/CT initiation
- 14 November 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 180 (2)
Open AccessLong-term socioeconomic, psychiatric, and societal burden in patients with grade 2 mIDH glioma and partner spillover burden, worsening with disease progression and RT/CT initiation
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag097
Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey
Background: Primary central nervous system (CNS) tumors are rare malignancies with limited treatment options, resulting in high mortality. Unlike other solid tumors, CNS tumors present unique challenges that impact the health-related quality of life (HRQoL) of patients and caregivers. Effective management requires balancing oncologic treatment with the control of neurocognitive deficits, epilepsy, and other neurological symptoms. Methods: The European Society for Medical Oncology (ESMO) CNS Faculty conducted a consensus process to identify the most pressing educational priorities for physicians managing CNS malignancies. This process involved structured data collection and expert input to determine critical areas for disease-specific education and training. Results: The consensus process highlighted key educational gaps in managing CNS tumors, emphasizing the need for a multidisciplinary approach to optimize therapeutic strategies, improve survival outcomes, enhance HRQoL during treatment and survivorship, and facilitate access to emerging therapies. Physicians reported that comprehensive, disease-specific education is essential to address these challenges effectively. Conclusion: CNS tumors require targeted educational initiatives to equip healthcare providers with the knowledge and skills necessary for optimal patient care. The ESMO CNS Faculty consensus underscores the importance of structured, disease-specific training to improve outcomes, support HRQoL, and advance oncology education in the management of CNS malignancies.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag097
Open AccessEducational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey
Background: Primary central nervous system (CNS) tumors are rare malignancies with limited treatment options, resulting in high mortality. Unlike other solid tumors, CNS tumors present unique challenges that impact the health-related quality of life (HRQoL) of patients and caregivers. Effective management requires balancing oncologic treatment with the control of neurocognitive deficits, epilepsy, and other neurological symptoms. Methods: The European Society for Medical Oncology (ESMO) CNS Faculty conducted a consensus process to identify the most pressing educational priorities for physicians managing CNS malignancies. This process involved structured data collection and expert input to determine critical areas for disease-specific education and training. Results: The consensus process highlighted key educational gaps in managing CNS tumors, emphasizing the need for a multidisciplinary approach to optimize therapeutic strategies, improve survival outcomes, enhance HRQoL during treatment and survivorship, and facilitate access to emerging therapies. Physicians reported that comprehensive, disease-specific education is essential to address these challenges effectively. Conclusion: CNS tumors require targeted educational initiatives to equip healthcare providers with the knowledge and skills necessary for optimal patient care. The ESMO CNS Faculty consensus underscores the importance of structured, disease-specific training to improve outcomes, support HRQoL, and advance oncology education in the management of CNS malignancies.
- Open Access
- 2 November 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1489-1496
3D Swin Transformer for patient-specific proton dose prediction of brain cancer patients
Background and purpose: Accurate dose plans in proton radiotherapy with consistent target in complex anatomical regions such as the brain are crucial. This study investigates a Swin Transformer-based deep learning model for voxel-wise dose prediction in brain cancer proton therapy, evaluating its spatial and dosimetric fidelity against clinically delivered plans. Patient/material and methods: A cohort of 206 patients with primary brain tumors were retrospectively analyzed. Dual-energy computed tomography (CT) scans, clinical contours, and corresponding proton dose plans were used to train and test a 3D Swin Transformer integrated within a UNet architecture. The model was evaluated on an independent test set (n = 20) using 3D gamma analysis (3%/3 mm), mean absolute error (MAE), and clinical target volume (CTV) coverage (V95%). Mean dose-volume histograms (DVHs) were compared across CTV. Results: The model achieved a median gamma pass rate of 99.8% within the CTV (range: 78.6–100%), 83.2% outside the CTV (range: 52.3–99.8%), and a whole-volume median pass rate of 90.0% (range: 53.7–99.8%). The median MAE was 0.72 Gy (range: 0.2816–1.8966 Gy). Predicted dose distributions preserved high-dose conformity, with a median of V95% of 97.9% (range: 78.8–100%). DVH curves closely matched the clinical reference plans across all evaluated structures. Interpretation: The proposed Swin Transformer-based model is a step toward accurate, anatomy-aware dose prediction for brain tumor proton therapy. Future work will address prospective validation and optimization for clinical deployment.
- 2 November 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1489-1496
Open Access3D Swin Transformer for patient-specific proton dose prediction of brain cancer patients
Background and purpose: Accurate dose plans in proton radiotherapy with consistent target in complex anatomical regions such as the brain are crucial. This study investigates a Swin Transformer-based deep learning model for voxel-wise dose prediction in brain cancer proton therapy, evaluating its spatial and dosimetric fidelity against clinically delivered plans. Patient/material and methods: A cohort of 206 patients with primary brain tumors were retrospectively analyzed. Dual-energy computed tomography (CT) scans, clinical contours, and corresponding proton dose plans were used to train and test a 3D Swin Transformer integrated within a UNet architecture. The model was evaluated on an independent test set (n = 20) using 3D gamma analysis (3%/3 mm), mean absolute error (MAE), and clinical target volume (CTV) coverage (V95%). Mean dose-volume histograms (DVHs) were compared across CTV. Results: The model achieved a median gamma pass rate of 99.8% within the CTV (range: 78.6–100%), 83.2% outside the CTV (range: 52.3–99.8%), and a whole-volume median pass rate of 90.0% (range: 53.7–99.8%). The median MAE was 0.72 Gy (range: 0.2816–1.8966 Gy). Predicted dose distributions preserved high-dose conformity, with a median of V95% of 97.9% (range: 78.8–100%). DVH curves closely matched the clinical reference plans across all evaluated structures. Interpretation: The proposed Swin Transformer-based model is a step toward accurate, anatomy-aware dose prediction for brain tumor proton therapy. Future work will address prospective validation and optimization for clinical deployment.
- Open Access
- 1 September 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (2) , 331-341
Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma
Background: IDH-mutant (mIDH) gliomas affect relatively young and otherwise healthy patients with high workforce participation. Management typically involves surgery, radiotherapy, and/or chemotherapy (RT/CT), although immediate post-surgery treatment may be deferred in favor of active observation (AO) to preserve functioning. This study aimed to evaluate how disease progression and treatments impact work activity, medical and societal costs, and overall survival (OS) in grade 2 mIDH glioma patients initially managed with AO. Methods: This retrospective longitudinal study utilized Danish administrative registries. Patients with mIDH gliomas initially managed with AO between 2010 and 2022 were included. Employment rates, sick leaves, treatment patterns, medical resources and costs, and OS were examined from diagnosis to the end of follow-up or death. Results: Data from 237 patients were analyzed; 72.9% were alive at 10 years. After surgical recovery, ability to work was most impaired during RT/CT, necessitating nearly full-time sick leave. Work activity continuously decreased after each RT/CT treatment. Employment rates were similarly affected, from under 20% unemployment at baseline and during AO, up to 41% and 59% after first and second RT/CT. Similar trends were observed for medical resources and costs, and productivity losses. Conclusions: Patients with grade 2 mIDH glioma remain active at work after initial surgery when managed with AO. Work impairment increases over successive RT/CT courses, highlighting the need to preserve quality of life by integrating work ability into clinical practice and by developing new treatment strategies to delay aggressive therapies and avoid substantial medical and productivity costs.
- 1 September 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (2) , 331-341
Open AccessEvaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma
Background: IDH-mutant (mIDH) gliomas affect relatively young and otherwise healthy patients with high workforce participation. Management typically involves surgery, radiotherapy, and/or chemotherapy (RT/CT), although immediate post-surgery treatment may be deferred in favor of active observation (AO) to preserve functioning. This study aimed to evaluate how disease progression and treatments impact work activity, medical and societal costs, and overall survival (OS) in grade 2 mIDH glioma patients initially managed with AO. Methods: This retrospective longitudinal study utilized Danish administrative registries. Patients with mIDH gliomas initially managed with AO between 2010 and 2022 were included. Employment rates, sick leaves, treatment patterns, medical resources and costs, and OS were examined from diagnosis to the end of follow-up or death. Results: Data from 237 patients were analyzed; 72.9% were alive at 10 years. After surgical recovery, ability to work was most impaired during RT/CT, necessitating nearly full-time sick leave. Work activity continuously decreased after each RT/CT treatment. Employment rates were similarly affected, from under 20% unemployment at baseline and during AO, up to 41% and 59% after first and second RT/CT. Similar trends were observed for medical resources and costs, and productivity losses. Conclusions: Patients with grade 2 mIDH glioma remain active at work after initial surgery when managed with AO. Work impairment increases over successive RT/CT courses, highlighting the need to preserve quality of life by integrating work ability into clinical practice and by developing new treatment strategies to delay aggressive therapies and avoid substantial medical and productivity costs.
- Open Access
- 21 July 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 889-893
Prediction model for the selection of patients with glioma to proton therapy
Background and purpose: The selection of patients with low-grade gliomas for proton therapy (PT) is often based on the comparison of photon and PT plans and demonstrating meaningful dose reduction to the healthy brain or critical structures. The aim of this retrospective study was to identify clinical parameters associated with referral to PT and build a prediction model. Patients and methods: The dataset consisted of patients with isocitrate dehydrogenase (IDH)-mutant grades 2 and 3 glioma and candidates for PT at the Aarhus University Hospital. Clinical (age, diagnosis, clinical target volume [CTV], and treatment) and dosimetric (prescribed dose and mean dose (Dmean) to healthy brain) parameters were collected. Univariate and multivariate logistic regression were used to assess the association with selection for PT. The dataset was split into training (n = 37, period 2019–2022) and test (n = 12, period 2023) cohorts. Prediction models were built using logistic regression algorithms and support vector machines (SVMs) and evaluated using the area under the precision-recall curve (AUC-PR). Results: Age (p = 0.03) and CTV (p = 0.01) were significantly associated with the selection for PT and were used for model prediction. The logistic regression demonstrated AUC-PR at 0.999 (CI 0.999–1.000) and 0.998 (0.996–1.000) for training and test cohorts, respectively. SVM showed similar results with AUC-PR at 0.993 (0.993–0.994) for training and 0.999 (0.998–1.000) for test cohorts. Interpretation: Logistic regression and SVM using age and CTV performed equally well and achieved a very high positive predictive value. With the pending external validation in a larger dataset, the prospects of this work suggest more consistent and efficient patient referral for PT.
- 21 July 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 889-893
Open AccessPrediction model for the selection of patients with glioma to proton therapy
Background and purpose: The selection of patients with low-grade gliomas for proton therapy (PT) is often based on the comparison of photon and PT plans and demonstrating meaningful dose reduction to the healthy brain or critical structures. The aim of this retrospective study was to identify clinical parameters associated with referral to PT and build a prediction model. Patients and methods: The dataset consisted of patients with isocitrate dehydrogenase (IDH)-mutant grades 2 and 3 glioma and candidates for PT at the Aarhus University Hospital. Clinical (age, diagnosis, clinical target volume [CTV], and treatment) and dosimetric (prescribed dose and mean dose (Dmean) to healthy brain) parameters were collected. Univariate and multivariate logistic regression were used to assess the association with selection for PT. The dataset was split into training (n = 37, period 2019–2022) and test (n = 12, period 2023) cohorts. Prediction models were built using logistic regression algorithms and support vector machines (SVMs) and evaluated using the area under the precision-recall curve (AUC-PR). Results: Age (p = 0.03) and CTV (p = 0.01) were significantly associated with the selection for PT and were used for model prediction. The logistic regression demonstrated AUC-PR at 0.999 (CI 0.999–1.000) and 0.998 (0.996–1.000) for training and test cohorts, respectively. SVM showed similar results with AUC-PR at 0.993 (0.993–0.994) for training and 0.999 (0.998–1.000) for test cohorts. Interpretation: Logistic regression and SVM using age and CTV performed equally well and achieved a very high positive predictive value. With the pending external validation in a larger dataset, the prospects of this work suggest more consistent and efficient patient referral for PT.
- Open Access
- 22 May 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 209, 110950
Recommendations for radiotherapy quality assurance in clinical trials
- 22 May 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 209, 110950
Open AccessRecommendations for radiotherapy quality assurance in clinical trials
- Open Access
- 6 November 2024
- Published by Elsevier in Clinical Oncology
- Vol. 37, 103682
REMIT: Reirradiation of Diffuse Midline Glioma Patients –A Nordic Society of Paediatric Haematology and Oncology Feasibility Study
- 6 November 2024
- Published by Elsevier in Clinical Oncology
- Vol. 37, 103682
Open AccessREMIT: Reirradiation of Diffuse Midline Glioma Patients –A Nordic Society of Paediatric Haematology and Oncology Feasibility Study
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6140
Abstract 6140: Transcriptional evolution of glioblastoma reveals changes in bulk composition, mesenchymal sub-type as end-state, and a prognostic association with increased extracellular matrix gene expression
Background: Glioblastoma is the most prevalent and severe type of malignant brain tumor in adults. Although the genetic make-up initiating glioblastoma is increasingly better understood, a better understanding in the mechanisms that drive its evolution, heterogeneity and therapy resistance may reveal new directions for therapy development. To get better insights into glioblastoma evolution, we analyzed and de-convoluted transcriptomes of primary and recurrent glioblastoma resections. Material and Methods: Matching primary and secondary resections from n=185 glioblastoma patients were collected as part of EORTC Study 1542. The study was extended with tumor pairs from n=51 patients from the international GLASS study. The datasets were subjected to differential and deconvolution analysis using in-house algorithms. Results: When mapping the tumor samples into a reduced Glioblastoma Intrinsic Transcriptional Subtype space, we visualized subtype traversal, indicating that the CL subtype most often switches. As we found no more transitions from MES to other subtypes than to be expected by chance, we concluded that MES is an end-state. On average, tumor cell percentages decreased from ~67% to ~50% mostly due to an increase in TAM/microglia. Differential expression analysis was performed with correction for tumor cell percentages. While expression of most known oncogenes did not change considerably over time, marker genes of TAM/microglia, neurons and oligodendrocytes were up-regulated whereas endothelial cell markers were down-regulated over time. Furthermore, a cluster of ~30 extracellular matrix-associated genes increase significantly over time. A signature representing the gene-set was significantly associated with poor survival; high signatures were in particular associated to survival in secondary resections (P = 6.613e-06, Kaplan-Meier estimator). This suggests that the increase of extracellular matrix expression fulfils an important role in glioblastoma evolution. Conclusion: Using a large cohort, we interrogated changes in the glioblastoma transcriptome over time and found that in particular the composition of the tumor and its environment changes. The tumor cell percentage drops, suggesting more invasion or recruitment of non-malignant cells or a combination of both. This change is independent of an increase in the prognostic increase in extracellular matrix expression. Citation Format: Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai, Iris de Heer, Levi van Hijfte, Wouter Coppieters, Melissa Kerkhof, Astrid Weyerbrock, Marc Sanson, Ann Hoeben, Slávka Lukacova, Giuseppe Lombardi, Sieger Leenstra, Monique Hanse, Ruth Fleischeuer, Colin Watts, Joseph McAbee, Nicos Angelopoulos, Thierry Gorlia, Vassilis Golfinopoulos, Johan M. Kros, Vincent Bours, Martin J. van den Bent, Pierre A. Robe, Pim J. French. Transcriptional evolution of glioblastoma reveals changes in bulk composition, mesenchymal sub-type as end-state, and a prognostic association with increased extracellular matrix gene expression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6140.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6140
Open AccessAbstract 6140: Transcriptional evolution of glioblastoma reveals changes in bulk composition, mesenchymal sub-type as end-state, and a prognostic association with increased extracellular matrix gene expression
Background: Glioblastoma is the most prevalent and severe type of malignant brain tumor in adults. Although the genetic make-up initiating glioblastoma is increasingly better understood, a better understanding in the mechanisms that drive its evolution, heterogeneity and therapy resistance may reveal new directions for therapy development. To get better insights into glioblastoma evolution, we analyzed and de-convoluted transcriptomes of primary and recurrent glioblastoma resections. Material and Methods: Matching primary and secondary resections from n=185 glioblastoma patients were collected as part of EORTC Study 1542. The study was extended with tumor pairs from n=51 patients from the international GLASS study. The datasets were subjected to differential and deconvolution analysis using in-house algorithms. Results: When mapping the tumor samples into a reduced Glioblastoma Intrinsic Transcriptional Subtype space, we visualized subtype traversal, indicating that the CL subtype most often switches. As we found no more transitions from MES to other subtypes than to be expected by chance, we concluded that MES is an end-state. On average, tumor cell percentages decreased from ~67% to ~50% mostly due to an increase in TAM/microglia. Differential expression analysis was performed with correction for tumor cell percentages. While expression of most known oncogenes did not change considerably over time, marker genes of TAM/microglia, neurons and oligodendrocytes were up-regulated whereas endothelial cell markers were down-regulated over time. Furthermore, a cluster of ~30 extracellular matrix-associated genes increase significantly over time. A signature representing the gene-set was significantly associated with poor survival; high signatures were in particular associated to survival in secondary resections (P = 6.613e-06, Kaplan-Meier estimator). This suggests that the increase of extracellular matrix expression fulfils an important role in glioblastoma evolution. Conclusion: Using a large cohort, we interrogated changes in the glioblastoma transcriptome over time and found that in particular the composition of the tumor and its environment changes. The tumor cell percentage drops, suggesting more invasion or recruitment of non-malignant cells or a combination of both. This change is independent of an increase in the prognostic increase in extracellular matrix expression. Citation Format: Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai, Iris de Heer, Levi van Hijfte, Wouter Coppieters, Melissa Kerkhof, Astrid Weyerbrock, Marc Sanson, Ann Hoeben, Slávka Lukacova, Giuseppe Lombardi, Sieger Leenstra, Monique Hanse, Ruth Fleischeuer, Colin Watts, Joseph McAbee, Nicos Angelopoulos, Thierry Gorlia, Vassilis Golfinopoulos, Johan M. Kros, Vincent Bours, Martin J. van den Bent, Pierre A. Robe, Pim J. French. Transcriptional evolution of glioblastoma reveals changes in bulk composition, mesenchymal sub-type as end-state, and a prognostic association with increased extracellular matrix gene expression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6140.
- 1 July 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 148, 1-7
Cognitive impairment following radiation to hippocampus and other brain structures in adults with primary brain tumours
- 1 July 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 148, 1-7
Cognitive impairment following radiation to hippocampus and other brain structures in adults with primary brain tumours
- 15 July 2019
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 58 (10) , 1532-1535
Individualizing the radiotherapy target volume for glioblastoma using DTI-MRI: a phase 0 study on coverage of recurrences
Glioblastoma (GBM) is the most aggressive malignant brain tumor leading to a dismal prognosis. The median overall survival (OS) is only 15 months despite extensive tri-modality treatment. The curre...
- 15 July 2019
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 58 (10) , 1532-1535
Individualizing the radiotherapy target volume for glioblastoma using DTI-MRI: a phase 0 study on coverage of recurrences
Glioblastoma (GBM) is the most aggressive malignant brain tumor leading to a dismal prognosis. The median overall survival (OS) is only 15 months despite extensive tri-modality treatment. The curre...